Can You Die From HIV? How Opportunistic Infections Develop

Untreated HIV infection is fatal in the vast majority of cases, typically progressing to AIDS and death within about seven to twelve years depending on age at infection. But modern antiretroviral therapy has transformed HIV from a death sentence into a chronic, manageable condition. With early diagnosis and consistent treatment, life expectancy now approaches that of the general population. The gap between those two realities, and the many factors that determine which one a person faces, is where the real story lies.

How Untreated HIV Kills

HIV does not kill directly the way, say, Ebola does. Instead, it targets and destroys CD4+ T cells, a type of immune cell that coordinates the body’s defense against infections and certain cancers. Over time, the virus drives a steady decline in these cells, hollowing out the immune system until it can no longer protect the body from threats it would normally handle with ease.¹ When CD4 counts drop below a critical threshold (roughly 200 cells per microliter of blood), the person is said to have AIDS, and infections that a healthy immune system would shrug off become life-threatening.

After the initial infection, HIV enters a chronic phase where viral loads stabilize and CD4 counts decline at a relatively steady pace.² Many people feel fine during this phase, which can last years. That silence is deceptive. Without treatment, the immune system is slowly being dismantled, and the person becomes progressively more vulnerable. A large evidence synthesis of seroconverter cohorts found that median survival without treatment ranged from about 12.5 years for people infected between ages 15 and 24, down to about 7 years for those infected between ages 45 and 54.³ Older age at infection meant faster CD4 decline and higher mortality.

What Actually Kills People With AIDS

The immediate cause of death in AIDS is almost always an opportunistic infection or cancer that takes advantage of the collapsed immune system. In a large study of hospitalized patients with HIV in southwestern China, the most common opportunistic infections were pneumonia, tuberculosis, and candidiasis (a fungal infection). Cryptococcal meningitis carried particularly high mortality, killing nearly a quarter of those who developed it.⁴

Brain infections remain a serious threat as well. Conditions like cerebral toxoplasmosis, progressive multifocal leukoencephalopathy, and tuberculous meningitis continue to cause significant illness and death among people with HIV, even in the era of treatment.⁵

Tuberculosis deserves special mention. It is the single biggest infectious killer of people with HIV worldwide. A systematic review and meta-analysis found that in-hospital mortality from TB among adults with HIV was about 25%, and among children it was roughly 30%.⁶ HIV weakens the immune response to TB bacteria, making infection more likely and harder to survive.

Certain cancers are also strongly linked to advanced HIV. Kaposi sarcoma, non-Hodgkin lymphoma, primary central nervous system lymphoma, and cervical cancer are classified as AIDS-defining cancers, meaning their appearance in someone with HIV signals that the disease has reached its most advanced stage. Although the rates of these cancers have dropped since the introduction of modern treatment, they remain more common in people with HIV than in the general population.⁷

How Treatment Changed the Equation

Antiretroviral therapy, which became widely available in the mid-1990s, fundamentally altered the natural course of HIV. The drugs suppress viral replication to undetectable levels, allowing the immune system to recover. With early diagnosis and timely treatment, life expectancy for people with HIV now closely approaches that of the general population.⁸

A large collaborative analysis of cohort studies in Europe and North America put specific numbers on this. Among men who started treatment after 2015 and had well-recovered immune systems (CD4 counts of at least 500), life expectancy was only about 1.5 years shorter than that of the general male population. For women in the same category, the gap was about 3.8 years. But for people whose CD4 counts remained low a year after starting treatment, estimated life expectancy could be up to 30 years shorter than that of the general population.⁹ The takeaway is clear: treatment works, but it works best when the immune system has not already been severely damaged.

One modeling study found that starting treatment when CD4 counts are still between 200 and 350 cells per microliter added roughly 14.5 years of life compared to no treatment.¹⁰ Starting even earlier, while counts are above 500, provides further benefit. A large retrospective study from China found that beginning treatment within 30 days of diagnosis was associated with a roughly 63% reduction in overall mortality among people with high CD4 counts.¹¹

Why Late Diagnosis Is So Dangerous

The biggest single predictor of whether someone dies from HIV today is how late they are diagnosed. People who learn their status only after their immune systems are already severely compromised face dramatically worse outcomes, even after starting treatment. A study analyzing HIV diagnosis trends from 2007 to 2023 found that delay in diagnosis roughly doubled the risk of death even after adjusting for other factors.¹² A cohort study in Ethiopia found an even starker picture: people diagnosed late (with CD4 counts already below 350) had more than three times the risk of dying compared to those diagnosed earlier.¹³

The numbers are particularly grim in the first year after a late diagnosis. One study found that people diagnosed late had nearly seven times the risk of dying from any cause in the short term, and nearly all HIV-related deaths occurring within the first year were attributable to late presentation.¹⁴ This is the cruelest irony of HIV in the treatment era: the virus is survivable, but only if you know you have it.

How People With Treated HIV Die Today

As AIDS-related deaths have declined, the causes of death among people on treatment have shifted to look more like those of the general aging population, but with some persistent differences. A collaborative analysis spanning 1996 to 2020 found that the proportion of deaths from AIDS dropped from about half in the late 1990s to about 16% by 2016–2020. Meanwhile, cancer deaths rose from 5% to 19% over the same period.¹⁵ Data from Switzerland confirmed the same trend: liver-related deaths decreased, non-AIDS cancers increased, and cardiovascular deaths stayed roughly stable.¹⁶

Cardiovascular disease has become a particular concern. HIV infection is associated with increased risk of atherosclerotic heart disease, likely driven by chronic inflammation that persists even when the virus is well controlled by medication. Inflammatory markers like interleukin-6, C-reactive protein, and D-dimer are independent predictors of death, including cardiovascular death, in people with HIV.¹⁷ The virus seems to leave a lasting inflammatory footprint on the body even when suppressed, and researchers are still working out how best to address it.

Non-AIDS-defining cancers, including lung, liver, and anal cancers, are also a growing source of illness and death among people living with HIV.¹⁸ Low CD4 count remains an important risk factor for dying from these cancers, along with smoking and viral hepatitis co-infection.¹⁹

When Hepatitis C Enters the Picture

Co-infection with hepatitis C is common among people living with HIV, especially those who contracted HIV through injection drug use. This combination is particularly damaging. HIV accelerates the progression of liver disease caused by hepatitis C, leading to cirrhosis, liver failure, and liver cancer at a faster rate than hepatitis C alone would cause.²⁰ Before effective hepatitis C treatments became available, end-stage liver disease was the leading cause of death in some cohorts of co-infected people, accounting for 20 to 25% of all deaths.²¹

A study from Poland quantified the toll: people co-infected with HIV and hepatitis C had a median life expectancy of about 55 years, compared to roughly 73 years for those with HIV alone. Overall mortality was more than twice as high in the co-infected group.²² Fortunately, highly effective hepatitis C cures are now available and have begun to reduce liver-related deaths in co-infected populations, but many people worldwide still lack access to these treatments.

Drug Resistance and Treatment Failure

Antiretroviral therapy is not foolproof. HIV mutates rapidly, and if a person takes their medication inconsistently, or if they begin treatment with a virus that already carries resistance mutations, the drugs can fail to suppress the virus. A systematic review and pooled analysis found that even low-frequency drug-resistant variants more than doubled the risk of treatment failure. Among people in that analysis who harbored resistant variants, about 35% experienced failure, compared to 15% of those without them.²³

This is an especially pressing issue in low- and middle-income countries where the most commonly available first-line drugs are the same class most likely to be affected by pre-existing resistance. A large meta-analysis found that people who had previously been exposed to antiretroviral drugs before starting a standard first-line regimen had nearly three times the risk of treatment failure at 12 months.²⁴ When first-line treatment fails, switching to second- or third-line regimens is possible but they may be less available, more expensive, or harder to tolerate. Treatment failure does not automatically mean death, but it means the virus is replicating again, the immune system is taking damage, and the window for effective control is narrowing.

Children and HIV

HIV is far more lethal in children than in adults, particularly when acquired around birth. Without treatment, the disease progresses with alarming speed. A pooled analysis of African cohorts found that by age one, about 35% of infected children had died. By age two, that figure rose to roughly 52%.²⁵ The timing of infection matters as well. A meta-analysis found that children who acquired HIV during birth had about a 52% mortality rate by 12 months, compared to 26% for those who acquired it later through breastfeeding.²⁶

These numbers reflect settings where treatment was unavailable or delayed. When infants are diagnosed quickly and started on antiretroviral therapy, survival improves dramatically. But early infant diagnosis and treatment remain logistically difficult in many parts of the world, so pediatric HIV mortality continues to be disproportionately high in sub-Saharan Africa and other resource-limited regions.

The Global Inequality Problem

Whether HIV kills you depends, to a disturbing degree, on where you live. The vast majority of people with HIV are in low- and middle-income countries, where access to diagnosis, treatment, and ongoing care varies enormously. Social and economic factors strongly predict who gets infected, who gets treated, and who dies.²⁷ Many people living with HIV still have no access to prevention, care, or treatment. In well-resourced health systems, dying of HIV has become rare when people are engaged in care. In settings without reliable drug supply chains, laboratory monitoring, or healthcare infrastructure, it remains common.

This gap is not closing as fast as headlines about treatment advances might suggest. While global AIDS-related deaths have fallen substantially from their peak in the mid-2000s, the decline has slowed in recent years, and new infections continue to outpace the scale-up of treatment in some regions. The scientific capacity to keep people alive exists; the political and economic will to deliver it everywhere does not.

A Dangerous Complication of Starting Treatment

There is a paradox that catches many people off guard: sometimes starting HIV treatment can itself trigger a life-threatening reaction. When a severely immunocompromised person begins antiretroviral therapy, the recovering immune system can mount an overwhelming inflammatory response against infections that were already quietly present in the body. This is called immune reconstitution inflammatory syndrome, or IRIS. It is most common in people who start treatment with very low CD4 counts and who have undiagnosed infections, especially in the brain. Case reports include fatal outcomes where rapid neurological deterioration occurred shortly after treatment initiation.²⁸ IRIS is one more reason early diagnosis matters: people who start treatment before their immune systems collapse are far less likely to experience it.

Can HIV Be Cured?

A handful of people have been functionally cured of HIV, all through stem cell transplants from donors carrying a rare genetic mutation that makes cells resistant to the virus. The most well-known case is the “Berlin patient,” treated in 2007. More recent cases have confirmed the approach works: a report described a 63-year-old man who received a transplant from a sibling donor with the CCR5-delta-32 mutation and showed no detectable HIV in blood or gut tissue nearly five years later, with no antiretroviral therapy.²⁹ Mathematical modeling of an earlier case suggested that once donor cells replaced more than 80% of the recipient’s target cells, the probability of lifelong remission exceeded 98%.³⁰

These cases are proof of concept, not a practical solution. Stem cell transplants are dangerous procedures reserved for people who need them for cancer treatment. They require matched donors, carry a substantial risk of death from the transplant itself, and are far too risky and expensive to offer to the millions of people living with HIV worldwide. Researchers are pursuing gene therapy, therapeutic vaccines, and other strategies aimed at a scalable cure, but none is close to clinical use. For now, daily antiretroviral therapy remains the tool that keeps people alive, and it works extraordinarily well when people can access it and take it consistently.